Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors

Conclusion Further investigations of the OBP-801 1.0  mg/m2 dose will be needed to better understand the efficacy of the agent, either alone or in combination.Trial registration: NCT02414516 (ClinicalTrials.gov) registered on April 10, 2015.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research